PRN: Global Gastrointestinal Partnering Report 2010-2017: Deal Trends, Players and Financials Analysis

08/set/2017 13:30:12 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Gastrointestinal Partnering Report 2010-2017: Deal Trends, Players and Financials Analysis

 
[08-September-2017]
 

DUBLIN, September 8, 2017 /PRNewswire/ --

The "Global Gastrointestinal Partnering 2010-2017: Deal trends, players and financials" report has been added to Research and Markets' offering.

Research and Markets Logo

Global Gastrointestinal Partnering 2010 to 2017 provides the full collection of Gastrointestinal disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Gastrointestinal disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Gastrointestinal deals.

The report presents financial deal terms values for Gastrointestinal deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Gastrointestinal dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Gastrointestinal dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Gastrointestinal deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Gastrointestinal dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Gastrointestinal deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities.
!
Chapter 6 provides a comprehensive directory of all Gastrointestinal partnering deals by specific Gastrointestinal target announced since 2010. The chapter is organized by specific Gastrointestinal therapeutic target.

In addition, a comprehensive appendix is provided with each report of all Gastrointestinal partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Report scope:

  • Trends in Gastrointestinal dealmaking in the biopharma industry since 2010
  • Analysis of Gastrointestinal deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Gastrointestinal deal contract documents
  • Comprehensive access to over 3500 Gastrointestinal deal records
  • The leading Gastrointestinal deals by value since 2010
  • Most active Gastrointestinal dealmakers since 2010

In Global Gastrointestinal Partnering 2010 to 2017, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Gastrointestinal dealmaking

Chapter 3 -Financial deal terms for Gastrointestinal partnering

Chapter 4 - Leading Gastrointestinal deals and dealmakers

Chapter 5 - Gastrointestinal contract document directory

Chapter 6 - Gastrointestinal dealmaking by therapeutic target

For more information about this report visit https://www.researchandmarkets.com/research/vbctlj/global

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl